TITLE

ANIKA BEGINS INCERT-S ANTI-ADHESION THERAPY CLINICAL TRIAL

PUB. DATE
June 2004
SOURCE
Worldwide Biotech;Jun2004, Vol. 16 Issue 6, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the start of a clinical trial for the INCERT-S therapy from Anika Therapeutics Inc. of Woburn, Massachusetts. Uses of the INCERT-S therapy; Remarks from Charles H. Sherwood, president and CEO of Anika Therapeutics, regarding the product strategy of the company; Background on Anika Therapeutics.
ACCESSION #
13265007

 

Related Articles

  • Anika Therapeutics Reports First-Quarter 2011 Financial Results.  // Biomedical Market Newsletter;5/9/2011, p431 

    The article focuses on the financial results of Anika Therapeutics for the first quarter ended March 31, 2011. Anika offers tissue protection and repair products based on hyaluronic acid (HA) technology and its revenue and product gross margin decreased by 5% and 49.3% respectively, as compared...

  • Anika expects revenue and earnings shortfall for third quarter.  // Biotech Financial Reports;Oct99, p6 

    Reports on Woburn, Massachusetts-based Anika Therapeutics Inc.'s announcement of its revenue for the quarter ending September 30, 1999. Anticipation of lower-than-expected sales for the quarter; Impact of the August 1999 earthquake in Turkey on the company's revenue; Contact information.

  • ANIKA/ORTHO BIOTECH SIGN MULTI-YEAR LICENSE/SUPPLY PACT.  // Biotech Business;Feb2004, Vol. 17 Issue 2, p8 

    Reports on the licensing and supply agreement between Anika Therapeutics Inc. and Ortho Biotech Products, L.P. for the marketing of Orthovisc (R), a form of hyaluronic acid for treating pain in patients suffering from osteoarthritis of the knee.

  • PRODUCT NEWS.  // Medical Marketing & Media;Jun2001, Vol. 36 Issue 6, p22 

    Reports developments related to drug development in the U.S. as of June 2001. Approval on the use of Bayer Corporation's Avelox for treatment of uncomplicated skin and skin structure; Release of STAARVISC II, an injectable opthalmic viscoelastic product from Anika Therapeutics Inc.; Components...

  • Misonix in distribution accord with Anika.  // Medical Device Daily;6/3/2011, Vol. 15 Issue 107, p3 

    The article reports on a new five-year exclusive U.S. distribution agreement signed by Misonix of Farmingdale, New York with Anika Therapeutics of Bedford, Massachusetts.

  • Anika Therapeutics to Present at the 8h Annual Noble Financial Equity Conference on Jan 17.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article provides information on a presentation to be delivered by Kevin Quinlan, chief financial officer of Anoka Therapeutics Inc. at the 8th Annual Noble Financial Equity Conference to be held on January 17, 2012 in Hollywood, Florida.

  • AstraZeneca Gets FDA OK For Orphan Drug, Myalept.  // Chain Drug Review;3/17/2014, Vol. 36 Issue 5, p73 

    The article offers the U.S. health care industry news briefs as of March 17, 2014 including the Food and Drug Administration's approval for the sale of the Myalept drug by AstraZeneca, launch of Novartis AG's Bexsero drug and marketing approval for Monovisc drug to Anika Therapeutics Inc.

  • Anika Therapeutics Announces Date of 1st-Qtr 2012 Financial Results Conference Call.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article provides information on a conference call to be hosted by Anika Therapeutics Inc. on May 3, 2012 to discuss its financial results.

  • ANIKA THERAPEUTICS. Investor's Business Daily // Investors Business Daily;7/31/2014, pA02 

    The article reports that the earnings per share (EPS) of Anika Therapeutics Inc., maker of bone-healing products, have increased by 50% to 60 cents in the second quarter (Q2) of 2014.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics